Annual Revenue Comparison: PTC Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.

A Decade of Growth: PTC Therapeutics vs. Amphastar Pharmaceuticals

In the competitive landscape of biotechnology, PTC Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc. have shown remarkable revenue growth over the past decade. Since 2014, Amphastar's revenue has surged by over 200%, reaching its peak in 2023. Meanwhile, PTC Therapeutics has experienced an even more impressive growth trajectory, with revenues skyrocketing by approximately 400% during the same period.

Key Insights

• 2014-2017: Amphastar maintained a steady growth, while PTC Therapeutics began its upward climb, surpassing Amphastar in 2017.
• 2018-2020: Both companies saw significant revenue increases, with PTC Therapeutics consistently outpacing Amphastar.
• 2021-2023: PTC Therapeutics solidified its lead, achieving a revenue nearly 50% higher than Amphastar by 2023.

This data highlights the dynamic nature of the biotech industry and the potential for rapid growth driven by innovation and strategic market positioning.